|
US20040081653A1
(en)
*
|
2002-08-16 |
2004-04-29 |
Raitano Arthur B. |
Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
|
|
US7480593B2
(en)
*
|
2005-08-03 |
2009-01-20 |
Suresh Gopalan |
Methods and systems for high confidence utilization of datasets
|
|
EP2069793B9
(en)
|
2006-08-29 |
2017-08-16 |
Oxford BioTherapeutics Ltd |
Identification of protein associated with hepatocellular carcinoma, glioblastoma and lung cancer
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
EP2379595A2
(en)
*
|
2008-12-23 |
2011-10-26 |
AstraZeneca AB |
Targeted binding agents directed to 5 1 and uses thereof
|
|
WO2010087743A2
(en)
|
2008-12-30 |
2010-08-05 |
Cellartis Ab |
The use of a protein in stem cell and cancer applications
|
|
JP5816558B2
(ja)
|
2009-03-05 |
2015-11-18 |
メダレックス・リミテッド・ライアビリティ・カンパニーＭｅｄａｒｅｘ， Ｌ．Ｌ．Ｃ． |
Ｃａｄｍ１に特異的な完全ヒト抗体
|
|
EP2374816B1
(en)
*
|
2010-04-07 |
2016-09-28 |
Agency For Science, Technology And Research |
Binding molecules against Chikungunya virus and uses thereof
|
|
US9441032B2
(en)
|
2010-04-07 |
2016-09-13 |
Agency For Science, Technology And Research |
Binding molecules against Chikungunya virus and uses thereof
|
|
IL299365A
(en)
|
2010-05-27 |
2023-02-01 |
Genmab As |
Monoclonal antibodies against 2HER
|
|
NZ604007A
(en)
*
|
2010-05-27 |
2015-03-27 |
Genmab As |
Monoclonal antibodies against her2 epitope
|
|
MX381912B
(es)
*
|
2010-07-16 |
2025-03-13 |
Adimab Llc |
Colecciones de anticuerpos.
|
|
CA2809864A1
(en)
*
|
2010-09-03 |
2012-03-08 |
Stem Centrx, Inc. |
Identification and enrichment of cell subpopulations
|
|
CN106620693A
(zh)
*
|
2010-09-03 |
2017-05-10 |
艾伯维施特姆森特克斯有限责任公司 |
新型调节剂及使用方法
|
|
US9778264B2
(en)
|
2010-09-03 |
2017-10-03 |
Abbvie Stemcentrx Llc |
Identification and enrichment of cell subpopulations
|
|
AU2015234335B2
(en)
*
|
2010-09-29 |
2017-09-28 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
|
|
ES2874306T3
(es)
*
|
2010-09-29 |
2021-11-04 |
Agensys Inc |
Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
US9598496B2
(en)
|
2011-05-09 |
2017-03-21 |
Perseus Proteomics Inc. |
Antibody capable of specifically recognizing transferrin receptor
|
|
MX367743B
(es)
*
|
2011-12-05 |
2019-09-04 |
Trellis Bioscience Llc |
Anticuerpos utiles para la inmunizacion pasiva de influenza.
|
|
ES2886123T3
(es)
*
|
2012-01-31 |
2021-12-16 |
Regeneron Pharma |
Anticuerpos anti-asic1 y usos de los mismos
|
|
JP5939855B2
(ja)
*
|
2012-03-23 |
2016-06-22 |
国立大学法人 宮崎大学 |
トランスフェリン受容体抗体
|
|
HK1208181A1
(en)
|
2012-06-21 |
2016-02-26 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind c-met
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
DK2918603T3
(en)
*
|
2012-11-08 |
2018-10-15 |
Univ Miyazaki |
ANTIBODY STANDING TO SPECIFICALLY RECOGNIZE TRANSFERRIN RECEPTOR
|
|
WO2014080866A1
(ja)
|
2012-11-21 |
2014-05-30 |
一般財団法人化学及血清療法研究所 |
新規なヒト抗ｉｌ－１８抗体
|
|
IL241552B2
(en)
|
2013-03-14 |
2023-09-01 |
Contrafect Corp |
Preparation and methods based on neutralizing antibodies administered intranasally for increased therapeutic efficacy
|
|
CN105764526B
(zh)
|
2013-08-26 |
2020-12-15 |
生物技术研发公司 |
编码抗唾液酸化路易斯a抗原的人抗体的核酸
|
|
WO2015034052A1
(ja)
|
2013-09-05 |
2015-03-12 |
国立大学法人 宮崎大学 |
ヒトインテグリンａ６ｂ４と特異的に反応する抗体
|
|
RS64268B1
(sr)
|
2013-09-20 |
2023-07-31 |
Bristol Myers Squibb Co |
Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
AU2015214146B2
(en)
|
2014-02-04 |
2020-09-17 |
Contrafect Corporation |
Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
|
|
US10639370B2
(en)
|
2014-02-04 |
2020-05-05 |
Contrafect Corporation |
Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
|
|
EA201691765A1
(ru)
|
2014-03-14 |
2016-12-30 |
Новартис Аг |
Молекулы антител против lag-3 и их применения
|
|
US20170173005A1
(en)
|
2014-03-27 |
2017-06-22 |
Research Foundation Of The City University Of New York |
Method for detecting or treating triple negative breast cancer
|
|
KR102401595B1
(ko)
*
|
2014-05-09 |
2022-05-24 |
삼성전자주식회사 |
항 HER2 scFv 단편 및 이를 포함하는 항 c-Met/항 HER2 이중 특이 항체
|
|
US9975960B2
(en)
*
|
2014-05-09 |
2018-05-22 |
Samsung Electronics Co., Ltd. |
Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same
|
|
WO2016055609A1
(en)
|
2014-10-10 |
2016-04-14 |
Innate Pharma |
Cd73 blockade
|
|
RS62003B2
(sr)
|
2014-11-10 |
2025-01-31 |
Medimmune Ltd |
Vezujući molekuli specifični za cd73 i njihove upotrebe
|
|
JP6805142B2
(ja)
*
|
2014-11-21 |
2020-12-23 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｃｄ７３に対する抗体およびその使用
|
|
ES2826566T3
(es)
|
2014-11-21 |
2021-05-18 |
Bristol Myers Squibb Co |
Anticuerpos que comprenden regiones constantes pesadas modificadas
|
|
BR112017011170A2
(pt)
|
2014-12-18 |
2018-02-27 |
Hoffmann La Roche |
método para determinar a citotoxicidade dependente do complemento de uma composição
|
|
EP3259288B1
(en)
*
|
2015-02-20 |
2026-07-22 |
Innate Pharma |
Cd73 blockade
|
|
BR112017023872A2
(pt)
|
2015-05-04 |
2018-07-24 |
Cytomx Therapeutics Inc |
anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
|
|
AU2016258988A1
(en)
|
2015-05-04 |
2017-12-07 |
Cytomx Therapeutics, Inc |
Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
|
|
EP3315604A4
(en)
*
|
2015-06-25 |
2018-12-26 |
Kaneka Corporation |
Liquid injection method
|
|
ES2791990T3
(es)
*
|
2015-07-15 |
2020-11-06 |
Becton Dickinson Co |
Sistema y método para ajustar las mediciones de citometría
|
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
WO2017064043A1
(en)
|
2015-10-12 |
2017-04-20 |
Innate Pharma |
Cd73 blocking agents
|
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
|
EP3481869A4
(en)
|
2016-07-11 |
2020-02-26 |
Corvus Pharmaceuticals, Inc. |
ANTI-CD73 ANTIBODIES
|
|
MA45674A
(fr)
|
2016-07-15 |
2019-05-22 |
Takeda Pharmaceuticals Co |
Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
|
|
EP3344263A4
(en)
*
|
2016-08-04 |
2020-07-01 |
Memorial Sloan-Kettering Cancer Center |
CANCER ANTIGEN TARGETS AND USES THEREOF
|
|
US10617720B2
(en)
*
|
2016-10-20 |
2020-04-14 |
Miltenyi Biotech, GmbH |
Chimeric antigen receptor specific for tumor cells
|
|
RS67792B1
(sr)
|
2016-12-01 |
2026-03-31 |
Regeneron Pharma |
Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje
|
|
CA3046432A1
(en)
*
|
2016-12-13 |
2018-06-21 |
Astellas Pharma Inc. |
Anti-human cd73 antibody
|
|
CA3045376C
(en)
|
2017-01-24 |
2022-08-30 |
I-Mab |
Anti-cd73 antibodies and uses thereof
|
|
JP7301002B2
(ja)
|
2017-05-30 |
2023-06-30 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗ｌａｇ－３抗体または抗ｌａｇ－３抗体および抗ｐｄ－１もしくは抗ｐｄ－ｌ１抗体を含む組成物
|
|
WO2018222718A1
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Treatment of lag-3 positive tumors
|
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
US11220544B2
(en)
|
2017-07-14 |
2022-01-11 |
Cytomx Therapeutics, Inc. |
Anti-CD166 antibodies and uses thereof
|
|
MX2020007429A
(es)
|
2018-01-12 |
2020-10-15 |
Takeda Pharmaceuticals Co |
Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
|
|
AU2019227607C1
(en)
|
2018-02-27 |
2023-07-20 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
|
|
CN119431579A
(zh)
|
2018-03-09 |
2025-02-14 |
艾吉纳斯公司 |
抗cd73抗体及其使用方法
|
|
AU2019231172B2
(en)
|
2018-03-09 |
2023-08-24 |
Phanes Therapeutics, Inc. |
Anti-CD73 antibodies and uses thereof
|
|
EP3810610A1
(en)
|
2018-05-18 |
2021-04-28 |
Incyte Corporation |
Fused pyrimidine derivatives as a2a / a2b inhibitors
|
|
EP3569618A1
(en)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonizing cd73 antibody
|
|
CN117304191A
(zh)
|
2018-07-05 |
2023-12-29 |
因赛特公司 |
作为a2a/a2b抑制剂的稠合吡嗪衍生物
|
|
CN112041348B
(zh)
|
2018-07-25 |
2023-09-22 |
天境生物科技(上海)有限公司 |
抗cd73抗pd-l1双特异性抗体
|
|
EA202191201A1
(ru)
|
2018-12-03 |
2022-01-26 |
Эдженсис, Инк. |
Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения
|
|
KR102063341B1
(ko)
*
|
2018-12-31 |
2020-01-07 |
다이노나(주) |
Icam-1에 특이적으로 결합하는 항체 및 그의 용도
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
EP3947452A4
(en)
|
2019-03-29 |
2023-05-03 |
Lankenau Institute for Medical Research |
ANTI-NMDA RECEPTOR ANTIBODIES AND METHODS OF USE
|
|
WO2021050857A1
(en)
*
|
2019-09-13 |
2021-03-18 |
Memorial Sloan-Kettering Cancer Center |
Anti-cd371 antibodies and uses thereof
|
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
|
CN114828965B
(zh)
*
|
2019-12-18 |
2025-09-05 |
豪夫迈·罗氏有限公司 |
与hla-a2/mage-a4结合的抗体
|
|
CR20220317A
(es)
|
2020-01-03 |
2022-09-02 |
Incyte Corp |
Anticuerpos anti-cd73 y usos de estos
|
|
EP4084870A1
(en)
|
2020-01-03 |
2022-11-09 |
Incyte Corporation |
Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
|
|
US12703739B2
(en)
|
2020-01-12 |
2026-08-11 |
Vanderbilt University |
Human antibodies to rift valley fever virus
|
|
CN111738980B
(zh)
*
|
2020-05-14 |
2023-08-04 |
北京深睿博联科技有限责任公司 |
一种医学影像的显示方法、计算机设备及存储介质
|
|
CN115867582A
(zh)
*
|
2020-05-29 |
2023-03-28 |
朝途生物疗法株式会社 |
抗cd73抗体及其用途
|
|
CA3196496A1
(en)
|
2020-10-23 |
2022-04-28 |
Laurence David TOMS |
Lag-3 antagonist therapy for lung cancer
|
|
JP2024502005A
(ja)
|
2020-12-29 |
2024-01-17 |
インサイト・コーポレイション |
Ａ２ａ／ａ２ｂ阻害剤、ｐｄ－１／ｐｄ－ｌ１阻害剤、及び抗ｃｄ７３抗体を含む併用療法
|
|
KR102887692B1
(ko)
*
|
2021-05-21 |
2025-11-18 |
주식회사 지놈앤컴퍼니 |
항-bcam 항체 또는 그의 항원 결합 단편
|
|
KR20240019224A
(ko)
*
|
2021-06-08 |
2024-02-14 |
메르크 파텐트 게엠베하 |
Cd80 및/또는 cd86, 및 ox40l에 결합하는 단백질
|
|
JP2024532620A
(ja)
|
2021-08-30 |
2024-09-05 |
ラッセン・セラピューティクス１・インコーポレイテッド |
抗ＩＬ－１１Ｒα抗体
|
|
CN114137231B
(zh)
*
|
2022-01-29 |
2022-04-29 |
北京大有天弘科技有限公司 |
一种血型不规则抗体的检测试剂盒及其应用
|
|
US12187806B2
(en)
|
2022-03-04 |
2025-01-07 |
Development Center For Biotechnology |
Anti-CD73 antibodies and use thereof
|
|
WO2024040195A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
CN122029192A
(zh)
*
|
2023-04-13 |
2026-05-12 |
A&G 药品公司 |
针对前列腺素f2受体抑制剂的抗体和缀合物及其用途
|
|
EP4719352A1
(en)
|
2023-05-31 |
2026-04-08 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
US20250127728A1
(en)
|
2023-10-05 |
2025-04-24 |
Capstan Therapeutics, Inc. |
Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
US20250302763A1
(en)
|
2024-02-22 |
2025-10-02 |
Capstan Therapeutics, Inc. |
Immune engineering amplification
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|